CN100358890C - 喹唑啉衍生物类激酶抑制剂 - Google Patents

喹唑啉衍生物类激酶抑制剂 Download PDF

Info

Publication number
CN100358890C
CN100358890C CNB018173527A CN01817352A CN100358890C CN 100358890 C CN100358890 C CN 100358890C CN B018173527 A CNB018173527 A CN B018173527A CN 01817352 A CN01817352 A CN 01817352A CN 100358890 C CN100358890 C CN 100358890C
Authority
CN
China
Prior art keywords
methoxy
piperazinyl
carboxamide
compound
quinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018173527A
Other languages
English (en)
Chinese (zh)
Other versions
CN1633431A (zh
Inventor
A·潘迪
R·M·斯卡伯勒
松野研司
市村通朗
野本裕二
井出慎一
佃英次
入江纯子
小田祥二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Millennium Pharmaceuticals Inc
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Millennium Pharmaceuticals Inc filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of CN1633431A publication Critical patent/CN1633431A/zh
Application granted granted Critical
Publication of CN100358890C publication Critical patent/CN100358890C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB018173527A 2000-08-18 2001-08-17 喹唑啉衍生物类激酶抑制剂 Expired - Fee Related CN100358890C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22612200P 2000-08-18 2000-08-18
US60/226,122 2000-08-18

Publications (2)

Publication Number Publication Date
CN1633431A CN1633431A (zh) 2005-06-29
CN100358890C true CN100358890C (zh) 2008-01-02

Family

ID=22847639

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018173527A Expired - Fee Related CN100358890C (zh) 2000-08-18 2001-08-17 喹唑啉衍生物类激酶抑制剂

Country Status (24)

Country Link
US (5) US6982266B2 (enExample)
EP (3) EP1315715B1 (enExample)
JP (1) JP5073147B2 (enExample)
KR (1) KR100831116B1 (enExample)
CN (1) CN100358890C (enExample)
AT (1) ATE402169T1 (enExample)
AU (1) AU8544901A (enExample)
BR (1) BR0113356A (enExample)
CA (1) CA2426440C (enExample)
CY (1) CY1110460T1 (enExample)
CZ (1) CZ304061B6 (enExample)
DE (1) DE60134990D1 (enExample)
DK (1) DK1315715T3 (enExample)
EA (1) EA005809B1 (enExample)
ES (1) ES2311023T3 (enExample)
HU (1) HU228668B1 (enExample)
IL (2) IL154514A0 (enExample)
MX (1) MXPA03001359A (enExample)
NO (1) NO323782B1 (enExample)
NZ (1) NZ524461A (enExample)
PT (1) PT1315715E (enExample)
SI (1) SI1315715T1 (enExample)
WO (1) WO2002016351A1 (enExample)
ZA (1) ZA200301510B (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228668B1 (hu) * 2000-08-18 2013-05-28 Millennium Pharmaceuticals Kináz inhibitor kinazolin-származékok és az ezeket tartalmazó gyógyszerkészítmények
EP1309568B1 (en) 2000-08-18 2011-02-16 Millennium Pharmaceuticals, Inc. [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor
DE60143204D1 (de) 2000-08-18 2010-11-18 Kyowa Hakko Kirin Co Ltd N-aryl-ä4-Ä7-(alkoxy)Chinazolin-4-ylÜPiperazinylüCarboxamid-Verbindungen als PDGF-Rezeptoren Hemmer
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
WO2002072578A2 (en) 2001-03-08 2002-09-19 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
DE60205776T2 (de) 2001-12-27 2006-06-14 Theravance Inc Indolinon-derivative als protein-kinasehemmer
WO2004010942A2 (en) * 2002-07-31 2004-02-05 Smithkline Beecham Corporation Substituted heterocyclic compounds as modulators of the ccr5 receptor
US7195876B2 (en) 2002-08-09 2007-03-27 Theravance, Inc. Oncokinase fusion polypeptides associated with hyperproliferative and related disorders, nucleic acids encoding the same and methods for detecting and identifying the same
UA83814C2 (ru) * 2002-12-24 2008-08-26 Астразенека Аб Производные фосфонооксихиназолина и их фармацевтическое применение
CA2571421A1 (en) * 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CN101189239A (zh) * 2005-04-28 2008-05-28 休普基因公司 蛋白激酶抑制剂
CA2612459A1 (en) * 2005-07-20 2007-01-25 Millennium Pharmaceuticals, Inc. New crystal forms of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide
WO2007100880A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
WO2008053270A2 (en) * 2006-10-31 2008-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an egfr antagonist for the treatment of glomerolonephritis
JP5250901B2 (ja) * 2007-02-23 2013-07-31 学校法人慶應義塾 アニリノキナゾリン系化合物及びその用途
AU2008240188A1 (en) * 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2370417A2 (en) * 2008-11-21 2011-10-05 Millennium Pharmaceuticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
DK2734205T3 (en) 2011-07-21 2018-06-14 Tolero Pharmaceuticals Inc Heterocyclic Protein Kinase Inhibitors
CN102942529B (zh) * 2012-11-09 2015-06-24 贵州大学 4-(4-取代哌嗪)-5,6,7-三烷氧基喹唑啉类化合物及其制备方法和应用
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
CN103288760B (zh) * 2013-05-16 2015-02-18 苏州明锐医药科技有限公司 卡奈替尼的制备方法
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
AU2016245864C1 (en) 2015-04-10 2021-09-09 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
ES2856880T3 (es) 2015-04-15 2021-09-28 Araxes Pharma Llc Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058902A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356359B1 (en) 2015-09-28 2021-10-20 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10975071B2 (en) 2015-09-28 2021-04-13 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
JP2018533939A (ja) 2015-10-19 2018-11-22 アラクセス ファーマ エルエルシー Ｒａｓの阻害剤をスクリーニングするための方法
KR102932353B1 (ko) 2015-11-16 2026-02-27 아락세스 파마 엘엘씨 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
CN106083715A (zh) * 2016-06-01 2016-11-09 谢阳 一种喹啉、喹唑啉类化合物及其药物组合物和应用
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JP2019529484A (ja) 2016-09-29 2019-10-17 アラクセス ファーマ エルエルシー Ｋｒａｓ ｇ１２ｃ変異体タンパク質の阻害剤
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
TW201906832A (zh) 2017-05-25 2019-02-16 美商亞瑞克西斯製藥公司 用於癌症治療之化合物及其使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
BR112020020246A8 (pt) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc Inibidores de cinase axl e uso dos mesmos
CN108570039B (zh) * 2018-04-25 2022-09-23 上海美迪西生物医药股份有限公司 一类具有抑制抗凋亡蛋白活性的化合物及其制备和应用
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
HUE072069T2 (hu) 2019-02-12 2025-10-28 Sumitomo Pharma America Inc 2-((1R,4R)-4-((3-(3-(trifluormetil)fenil)imidazo[1,2- b]piridazin-6-il)amino)ciklohexil)propán-2-ol sósavas sójának kristályos formája
CN112300082B (zh) * 2019-07-26 2022-04-26 暨南大学 一种苯基哌嗪喹唑啉类化合物或其药学上可接受的盐、制法与用途
CN111773440B (zh) * 2020-05-22 2026-04-17 南京大学 一种基于类酶催化反应的抗凝血材料
US20250129067A1 (en) 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208404A (zh) * 1996-10-01 1999-02-17 协和发酵工业株式会社 含氮杂环化合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69222637T2 (de) 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
DE69943144D1 (de) * 1998-03-31 2011-03-03 Kyowa Hakko Kirin Co Ltd Stickstoffenthaltende heterocyclische verbindungen
DE60143204D1 (de) 2000-08-18 2010-11-18 Kyowa Hakko Kirin Co Ltd N-aryl-ä4-Ä7-(alkoxy)Chinazolin-4-ylÜPiperazinylüCarboxamid-Verbindungen als PDGF-Rezeptoren Hemmer
EP1309567A2 (en) 2000-08-18 2003-05-14 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds
HU228668B1 (hu) * 2000-08-18 2013-05-28 Millennium Pharmaceuticals Kináz inhibitor kinazolin-származékok és az ezeket tartalmazó gyógyszerkészítmények
EP1309568B1 (en) 2000-08-18 2011-02-16 Millennium Pharmaceuticals, Inc. [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor
WO2002072578A2 (en) 2001-03-08 2002-09-19 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
US7132427B2 (en) * 2001-06-21 2006-11-07 Ariad Pharmaceuticals, Inc. Quinazolines and uses thereof
US7456189B2 (en) * 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208404A (zh) * 1996-10-01 1999-02-17 协和发酵工业株式会社 含氮杂环化合物

Also Published As

Publication number Publication date
IL154514A (en) 2011-03-31
NZ524461A (en) 2004-12-24
KR100831116B1 (ko) 2008-05-20
US20100113468A1 (en) 2010-05-06
PT1315715E (pt) 2008-10-30
NO20030747D0 (no) 2003-02-17
CZ2003765A3 (cs) 2004-08-18
US20050101609A1 (en) 2005-05-12
WO2002016351A1 (en) 2002-02-28
HK1057206A1 (en) 2004-03-19
US20150133439A1 (en) 2015-05-14
EP2277877A1 (en) 2011-01-26
HU228668B1 (hu) 2013-05-28
US6982266B2 (en) 2006-01-03
EP1315715B1 (en) 2008-07-23
US8324205B2 (en) 2012-12-04
ES2311023T3 (es) 2009-02-01
AU2001285449B2 (en) 2007-04-05
EP1964839A3 (en) 2008-11-05
NO20030747L (no) 2003-04-14
ZA200301510B (en) 2004-06-22
CN1633431A (zh) 2005-06-29
HUP0302615A3 (en) 2008-03-28
KR20030082537A (ko) 2003-10-22
EP1964839A2 (en) 2008-09-03
US20130274252A1 (en) 2013-10-17
CA2426440C (en) 2011-03-15
BR0113356A (pt) 2004-04-20
CA2426440A1 (en) 2002-02-28
EA200300265A1 (ru) 2003-12-25
US7560461B2 (en) 2009-07-14
JP2005501796A (ja) 2005-01-20
EP1315715A1 (en) 2003-06-04
CY1110460T1 (el) 2015-04-29
MXPA03001359A (es) 2004-12-13
IL154514A0 (en) 2003-09-17
CZ304061B6 (cs) 2013-09-11
ATE402169T1 (de) 2008-08-15
HUP0302615A2 (hu) 2003-12-29
US20050288297A1 (en) 2005-12-29
SI1315715T1 (sl) 2008-12-31
EA005809B1 (ru) 2005-06-30
DK1315715T3 (da) 2008-11-17
JP5073147B2 (ja) 2012-11-14
NO323782B1 (no) 2007-07-02
DE60134990D1 (de) 2008-09-04
AU8544901A (en) 2002-03-04

Similar Documents

Publication Publication Date Title
KR100831116B1 (ko) 키나아제 억제제로서의 퀴나졸린 유도체
WO2021194321A1 (en) Benzimidazole thiophene derivative compounds inducing selective degradation of plk1
WO2021107657A1 (ko) 신규한 퀴나졸린 리독스 유도체 및 bet 억제제로서의 용도
WO2020262998A1 (ko) 항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물
ES2354039T3 (es) Derivados de n-aril-{4-[7-(alcoxi)quinazolin-4-il]piperazinil}carboxamida como inhibidores de pdgfr.
EP1309567A2 (en) Nitrogenous heterocyclic compounds
WO2017099424A1 (en) Novel dihydropyranopyrimidinone derivatives, and use thereof
WO2021201576A1 (ko) 벤조티아졸 유도체 화합물
US20040259881A1 (en) Nitrogenous heterocyclic compounds
WO2024144088A1 (en) Met protein degradation inducing compound
WO2025005748A1 (ko) 신규 셀레노펜 유도체
AU2001285449B8 (en) Quinazoline derivatives as kinase inhibitors
WO2025135855A1 (ko) Yap-tead 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물
EP4581027A1 (en) Novel heterobicyclic compound for inhibiting yap-tead interaction and pharmaceutical composition comprising same
HK1124316A (en) Quinazoline derivatives as kinase inhibitors
WO2023120963A1 (ko) 카바졸 유도체 화합물을 유효성분으로 포함하는 폐암 예방 또는 치료용 약학 조성물
WO2024101764A1 (ko) 퀴놀린 아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
AU2001285449A1 (en) Quinazoline derivatives as kinase inhibitors
HK1057206B (en) Quinazoline derivatives as kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080102

Termination date: 20150817

EXPY Termination of patent right or utility model